(Q37257892)

19 August 2017

1 reference

title

Structure-activity relationships of macrolides against Mycobacterium tuberculosis (English)

1 reference

Mycobacterium tuberculosis

19 August 2017

main subject

0 references

Scott G Franzblau

12

0 references

author name string

Zhaohai J Zhu

1

1 reference

19 August 2017

Olga Krasnykh

2

1 reference

19 August 2017

Dahua Pan

3

1 reference

19 August 2017

Valentina Petukhova

4

1 reference

19 August 2017

Gengli Yu

5

1 reference

19 August 2017

Yinghui Liu

6

1 reference

19 August 2017

Huiwen Liu

7

1 reference

19 August 2017

Saweon Hong

8

1 reference

19 August 2017

Yuehong Wang

9

1 reference

19 August 2017

Baojie Wan

10

1 reference

19 August 2017

Wenzhong Liang

11

1 reference

19 August 2017

publication date

1 August 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

88 Suppl 1

1 reference

19 August 2017

page(s)

S49-63

1 reference

Translation and protein synthesis: macrolides

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Natural and acquired macrolide resistance in mycobacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Drug susceptibility testing of Mycobacterium leprae in the BACTEC 460 system

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

In vitro and in vivo activities of macrolides against Mycobacterium leprae

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

In vitro effects of antimicrobial agents on Mycobacterium leprae in mouse peritoneal macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Clinical trial of clarithromycin for lepromatous leprosy

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Antibiotic susceptibility pattern of Mycobacterium marinum.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Treatment of infections caused by rapidly growing mycobacteria in the era of the newer macrolides

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Clarithromycin is inactive against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Antituberculosis activity of clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

In vitro susceptibility of Mycobacterium tuberculosis to a new macrolide antibiotic: RU-28965.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Methyltransferase Erm(37) slips on rRNA to confer atypical resistance in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Fighting tuberculosis: an old disease with new challenges.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Studies on macrolide antibiotics I. Synthesis and antibacterial activity of erythromycin A 9-O-substituted oxime ether derivatives against Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Molecular basis of clarithromycin activity against Mycobacterium avium and Mycobacterium smegmatis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

The macrolide-bacterium interaction and its biological basis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Chemical modification of erythromycin antibiotics. 4. Structure-activity relations of erythromycin esters

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Recent developments on ketolides and macrolides

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Interaction of the macrolide antibiotic azithromycin with lipid bilayers: effect on membrane organization, fluidity, and permeability

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

Ancestral antibiotic resistance in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970036-2

7 January 2021

10.1016/S1472-9792(08)70036-2

Identifiers

DOI

1 reference

19 August 2017

1 reference